Abivax secures € 15M non-dilutive financing from Kreos Capital
« We are very happy about the decision of Kreos Capital to provide us with this non-dilutive loan, as it allows Abivax to keep executing on its priority clinical programs in chronic inflammatory diseases according to plan » said Pr. Hartmut Ehrlich, CEO of Abivax.